KB407 is Krystal Biotech's redosable inhaled gene therapy candidate for cystic fibrosis, designed to deliver full-length wild-type CFTR to the lung independent of mutation class. Interim Phase 1 CORAL-1 data reported successful lung delivery and expression of wild-type CFTR in treated patients, and the company is advancing repeat-dosing registrational-intent CORAL-3 planning. The program remains investigational.
Krystal Biotech said IOLITE enrollment for KB803 is complete and it remains on track for KB803 and KB801 registrational data readouts in 2026. The company also reported FDA platform technology designations for KB407 and KB111 and continued VYJUVEK expansion.
Krystal Biotech is set to report fourth-quarter results with analysts expecting $1.58 a share on $106.16 million in revenue. Investors are watching Vyjuvek growth and pipeline programs including KB801, KB407 and KB707.
Krystal Biotech posted Q4 2025 net revenue of $107.1 million from Vyjuvek sales, with full-year revenue reaching $389.1 million. The company expanded to over 90 patients across Germany, France, and Japan while advancing its pipeline with new FDA designations.
